government budgets

Dependence on government spending: appropriations, shutdowns, budget cuts and procurement priorities.

Exposure · 19 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • AMRO Amaero Inc.

    Exposed“Defense and naval programs expose AMRO to appropriations, shutdowns and changing Department of War priorities; only one employee currently has a security clearance.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernAccounting issueCustomer concentration ·

    Titanium and refractory metal powder maker scales up for defense and aerospace; IPO funding extends runway only into Q2 2027

  • ARMP Armata Pharmaceuticals, Inc.

    Exposed“ARMP depends in significant part on government grants, whose availability and funding may change with policy, agency staffing, or budget priorities.”

    Latest 10-QQ3 FY2026NegativeBankruptcy / going concern ·

    AP-SA02 advances toward Phase 3 with FDA support and expanded MTEC funding, but a cash shortfall threatens development.

    • Revenue$3.2MYoY +173.6%
    • Net income$54.9Mvs −$26.7M year ago
  • BA Boeing

    Exposed“Government funding and shifting budget priorities may affect BDS awards and programs; fixed-price development work—including KC-46A, VC-25B, T-7A, MQ-25, Commercial Crew and satellites—faces technical, schedule and cost-overrun risks.”

    Latest 10-QQ3 FY2026Mixed ·

    Lapping the prior-year 777X charge drives the return to operating profit; Commercial Airplanes remains loss-making.

    • Revenue$24.2BYoY +3.9%
    • Net income−$116.0MYoY +97.8%
  • BRKR Bruker

    Exposed“During FY2025, funding disruptions—including reduced or delayed awards and changes to funding terms and allowable overhead—led customers to reduce or defer purchases of high-end instruments and services.”

    Latest 8-KLeadership change ·

    Board adds immunologist Eicke Latz as life-science work expands; declares $0.05/share quarterly dividend.

  • CVS CVS Health

    Exposed“Other risks include changing 340B conditions, potential Medicare/Medicaid funding or risk-adjustment changes, inflation, tariffs, labor and supply-chain costs, and consumer shifts toward value, grocery and digital retailers.”

    Latest 10-QQ3 FY2026Mixed ·

    Planned split separates Aetna and Caremark from CVS Pharmacy as insurance profitability improves and pharmacy pricing pressure persists.

    • Revenue$108.4BYoY +5.4%
    • Net income$2.2Bvs −$4.0B year ago
  • GD General Dynamics

    Exposed“U.S. defense-budget reductions or changing priorities”

    Latest 10-QQ3 FY2026PositiveLegal / investigation ·

    Virginia- and Columbia-class awards swell submarine backlog as Electric Boat accounting probes add risk.

    • Revenue$14.6BYoY +12.9%
    • Net income$1.2BYoY +16.1%
  • GE GE Aerospace

    Exposed“A key exposure is reliance on government funding: most Defense & Systems revenue depends on U.S. Department of War or equivalent international budgets.”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Engine maintenance and pricing fuel growth; planned Consolidated Precision Products deal would expand manufacturing capacity

    • Revenue$14.1BYoY +15.9%
    • Net income$2.3BYoY +6.1%
  • HEI HEICO

    Exposed“government spending reductions”

    Latest 10-QQ3 FY2026Positive ·

    Defense and aerospace demand accelerated Electronic Technologies growth, while Flight Support’s organic growth slowed.

    • Revenue$1.4BYoY +23.1%
    • Net income$235.4MYoY +32.8%
  • LMT Lockheed Martin

    Exposed“Continuing resolutions, budget cuts, government shutdowns, changing procurement priorities, and the Government’s right to terminate contracts for convenience could affect awards, production, and results.”

    Latest 10-QQ3 FY2026Positive ·

    Higher missile production and F-35 activity lift sales, but operating margins narrow.

    • Revenue$20.7BYoY +11.3%
    • Net income$1.8BYoY +14.0%
  • LYNX Lyntris Inc.

    Exposed“Government appropriations and shifting defense priorities are central risks.”

    Latest 424B4final IPO prospectusMixedAccounting issueControlled companyProceeds to insiders or debt ·

    Defense sensors and mission software supplier; company IPO proceeds chiefly repay lenders rather than fund expansion.

  • MCK McKesson Corporation

    Exposed“The business also remains exposed to evolving drug-pricing policy, the federal 340B program and government healthcare funding.”

    Latest 10-QQ2 FY2027Restructuring ·

    Precision Medicine Group and Spectrum Vision acquisitions expand specialty care as separation costs squeeze Medical-Surgical profit.

    • Revenue$111.0BYoY +7.6%
    • Net income$1.2BYoY +9.7%
  • NOC Northrop Grumman Corporation

    Exposed“U.S. government funding and payment delays, potential continuing resolutions or shutdowns”

    Latest 10-QQ3 FY2026 ·

    B-21 production capacity is expanding under an Air Force agreement, but future lot pricing remains unsettled.

    • Revenue$11.1BYoY +6.7%
    • Net income$1.1BYoY +2.2%
  • NOW ServiceNow

    Exposed“A greater use of 12-month U.S. federal agreements, often signed in Q3 around budget timing, may add quarterly variability.”

    Latest 10-QQ3 FY2026Restructuring ·

    Armis and Veza acquisitions expand the security platform as deal amortization and infrastructure spending squeeze margins.

    • Revenue$4.1BYoY +20.5%
    • Net income$277.0MYoY −44.8%
  • NUOX NuvOx Therapeutics, Inc.

    Exposed“Government funding is uncertain.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernRestatementAccounting issue ·

    Intravenous oxygen drug developer seeks $20M gross at IPO midpoint to advance NanO₂ trials, with glioblastoma results the next major test

  • PLTR Palantir Technologies

    Exposed“Federal spending cuts, shifting priorities, shutdowns, procurement delays, bid protests, contract reductions, and termination-for-convenience rights can delay, reduce, or end business.”

    Latest 10-QQ3 FY2026Positive ·

    U.S. commercial demand and deeper customer deployments push commercial revenue past government.

    • Revenue$2.3BYoY +95.9%
    • Net income$1.1BYoY +137.2%
  • RDEV Rothe Development, Inc.

    Exposed“Government funding and procurement decisions are central risks.”

    Latest S-1/Aamended IPO prospectusNegativeAccounting issueCustomer concentrationControlled company ·

    NASA spacewalk-training operator and engineering contractor earmarks ≈$2.4M of IPO proceeds for its controlling CEO

  • RTX

    Exposed“These multi-year undefinitized contract actions are subject to appropriations, award timing, and government priorities.”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Tomahawk and AMRAAM awards drive missile-capacity expansion, while a customer bankruptcy weighs on Pratt & Whitney profitability.

    • Revenue$25.0BYoY +11.1%
    • Net income$2.6BYoY +34.7%
  • RZAI ROZE AI INC.

    Exposed“Results are also exposed to construction and real-estate cycles, industrial investment, government budgets, project timing, price competition, and supplier or commodity cost increases on fixed-price work.”

    Latest 424B4final IPO prospectusNegativeBankruptcy / going concernControlled companyProceeds to insiders or debt ·

    South Korean wireless fire-detection supplier enters a direct listing after FY2025 revenue fell 72.1% Y/Y as construction projects stalled.

  • SEQC SeeQC, Inc.

    Exposed“The company also relies on strategic customers and partners, including IBM, NVIDIA, Rigetti, and IQM, and on government-funded programs subject to appropriations and administrative discretion.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issueCustomer concentration ·

    Quantum-control chip developer with an unfinished platform; commercial products supplied only ≈5% of FY2025 revenue

Feedback